These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 23438878)

  • 21. Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity.
    Chan SL; Jin S; Loh M; Brunham LR
    Pharmacogenomics; 2015; 16(10):1161-78. PubMed ID: 25978008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical association between pharmacogenomics and adverse drug reactions.
    Zhou ZW; Chen XW; Sneed KB; Yang YX; Zhang X; He ZX; Chow K; Yang T; Duan W; Zhou SF
    Drugs; 2015 Apr; 75(6):589-631. PubMed ID: 25895462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The challenges of developing a 'medical-grade' genome.
    van der Straaten T; Guchelaar HJ; Swen JJ
    Pharmacogenomics; 2012 Mar; 13(4):369-72. PubMed ID: 22379992
    [No Abstract]   [Full Text] [Related]  

  • 24. Osteoporosis pharmacogenomics: recent insights and future perspectives.
    Ostanek B; Marc J
    Pharmacogenomics; 2013 Apr; 14(5):451-4. PubMed ID: 23556441
    [No Abstract]   [Full Text] [Related]  

  • 25. Exome versus transcriptome sequencing in identifying coding region variants.
    Ku CS; Wu M; Cooper DN; Naidoo N; Pawitan Y; Pang B; Iacopetta B; Soong R
    Expert Rev Mol Diagn; 2012 Apr; 12(3):241-51. PubMed ID: 22468815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The future of pharmacogenetics in the treatment of migraine.
    Borro M; Guglielmetti M; Simmaco M; Martelletti P; Gentile G
    Pharmacogenomics; 2019 Nov; 20(16):1159-1173. PubMed ID: 31637960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenomic biomarkers for personalized medicine.
    Chen JJ; Lin WJ; Chen HC
    Pharmacogenomics; 2013 Jun; 14(8):969-80. PubMed ID: 23746190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genome diagnostics: next-generation sequencing, new genome-wide association studies and clinical challenges.
    Ziogas DE; Roukos DH
    Expert Rev Mol Diagn; 2011 Sep; 11(7):663-6. PubMed ID: 21902524
    [No Abstract]   [Full Text] [Related]  

  • 29. Genome-wide and Phenome-wide Approaches to Understand Variable Drug Actions in Electronic Health Records.
    Robinson JR; Denny JC; Roden DM; Van Driest SL
    Clin Transl Sci; 2018 Mar; 11(2):112-122. PubMed ID: 29148204
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacogenetics of statins: achievements, whole-genome analyses and future perspectives.
    Postmus I; Verschuren JJ; de Craen AJ; Slagboom PE; Westendorp RG; Jukema JW; Trompet S
    Pharmacogenomics; 2012 May; 13(7):831-40. PubMed ID: 22594514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacogenetics of allopurinol--making an old drug safer.
    Lam MP; Yeung CK; Cheung BM
    J Clin Pharmacol; 2013 Jul; 53(7):675-9. PubMed ID: 23381951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perspective on the use of genomic biomarkers in the clinical setting.
    Agúndez JA; Sinclair E
    Pharmacogenomics; 2014 Mar; 15(4):419-22. PubMed ID: 24624909
    [No Abstract]   [Full Text] [Related]  

  • 33. Interpreting the clinical utility of a pharmacogenomic marker based on observational association studies.
    Sorich MJ; Coory M
    Pharmacogenomics J; 2014 Feb; 14(1):1-5. PubMed ID: 24018622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Race, ethnicity, ancestry, and pharmacogenetics.
    Urban TJ
    Mt Sinai J Med; 2010; 77(2):133-9. PubMed ID: 20309922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deep sequencing and integrative genome analysis: approaching a new class of biomarkers and therapeutic targets for breast cancer.
    Zografos G; Liakakos T; Roukos DH
    Pharmacogenomics; 2013 Jan; 14(1):5-8. PubMed ID: 23252942
    [No Abstract]   [Full Text] [Related]  

  • 36. HLA and pharmacogenetics of drug hypersensitivity.
    Pavlos R; Mallal S; Phillips E
    Pharmacogenomics; 2012 Aug; 13(11):1285-306. PubMed ID: 22920398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An approach to identifying preclinical biomarkers of susceptibility to drug-induced toxicity.
    Lin WJ; Chen JJ
    Pharmacogenomics; 2011 Apr; 12(4):493-501. PubMed ID: 21521022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Availability of pharmacogenetic and pharmacogenomic information in anticancer drug monographs in France: personalized cancer therapy.
    Albertini L; Siest G; Jeannesson E; Visvikis-Siest S
    Pharmacogenomics; 2011 May; 12(5):681-91. PubMed ID: 21619430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmacogenetics: relevant aspects for the practicing veterinarian].
    Jud Schefer R; Paine Kuhn C; Demuth D
    Schweiz Arch Tierheilkd; 2012 Dec; 154(12):521-7. PubMed ID: 23188764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenomics arrives.
    Petsko GA
    Genome Biol; 2004; 5(6):108. PubMed ID: 15186481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.